Amgen Partners With Daiichi-Sankyo For Denosumab In Japan

Amgen and Daiichi-Sankyo have entered a collaboration and license agreement for development and commercialization of Amgen's investigational bone loss therapy denosumab in Japan, the companies announced July 11